Last reviewed · How we verify

NCT05974449

Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients

Recruiting now Phase 2 Last updated 12 December 2024
What this trial tests

Phase 2 trial testing Vaginal Lactobacillus capsules in Breast Cancer Female in 60 participants. Currently enrolling.

Timeline
24 August 2023
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorThe First Affiliated Hospital with Nanjing Medical University
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeprevention
Enrollment60
Start date24 August 2023
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 45, female only, with Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, randomized controlled, phase II clinical study with a planned enrolment of 60 patients. The study focuses on the efficacy and safety of Lactobacillus vaginalis capsules for the prevention and/or treatment of vulvovaginal symptoms in young breast cancer patients receiving ovarian protection during chemotherapy, in order to improve compliance and quality of life in breast cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Intestinal flora: a potential pathogenesis mechanism and treatment strategy for type 1 diabetes mellitus.
    Huang S, Li F, Quan C, Jin D. · · 2024 · cited 8× · PMID 39520706 · DOI 10.1080/19490976.2024.2423024

Verify or expand the search:

Other recruiting trials for Breast Cancer Female

Currently open trials in the same condition.

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05974449.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing